231 related articles for article (PubMed ID: 15199411)
1. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
Cheung WC; Kim JS; Linden M; Peng L; Van Ness B; Polakiewicz RD; Janz S
J Clin Invest; 2004 Jun; 113(12):1763-73. PubMed ID: 15199411
[TBL] [Abstract][Full Text] [Related]
2. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
Eischen CM; Woo D; Roussel MF; Cleveland JL
Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
[TBL] [Abstract][Full Text] [Related]
4. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
5. CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.
Han SS; Peng L; Chung ST; DuBois W; Maeng SH; Shaffer AL; Sporn MB; Janz S
Mol Cancer; 2006 Jun; 5():22. PubMed ID: 16759389
[TBL] [Abstract][Full Text] [Related]
6. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
7. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
8. IL-6 and MYC collaborate in plasma cell tumor formation in mice.
Rutsch S; Neppalli VT; Shin DM; DuBois W; Morse HC; Goldschmidt H; Janz S
Blood; 2010 Mar; 115(9):1746-54. PubMed ID: 20018915
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
[TBL] [Abstract][Full Text] [Related]
10. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
11. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.
Linden M; Kirchhof N; Carlson C; Van Ness B
Blood; 2004 Apr; 103(7):2779-86. PubMed ID: 14656874
[TBL] [Abstract][Full Text] [Related]
12. Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.
Vandenberg CJ; Waring P; Strasser A; Cory S
Blood; 2014 Aug; 124(7):1099-109. PubMed ID: 24986687
[TBL] [Abstract][Full Text] [Related]
13. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell tumour progression in iMycEmu gene-insertion mice.
Kim JS; Han SS; Park SS; McNeil N; Janz S
J Pathol; 2006 May; 209(1):44-55. PubMed ID: 16482495
[TBL] [Abstract][Full Text] [Related]
15. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
Park SS; Shaffer AL; Kim JS; duBois W; Potter M; Staudt LM; Janz S
Cancer Res; 2005 Sep; 65(17):7644-52. PubMed ID: 16140930
[TBL] [Abstract][Full Text] [Related]
16. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
17. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
Gauthier ER; Piché L; Lemieux G; Lemieux R
Cancer Res; 1996 Mar; 56(6):1451-6. PubMed ID: 8640839
[TBL] [Abstract][Full Text] [Related]
18. Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.
Hueber AO; Bösser S; Zörnig M
Int J Cancer; 2004 Nov; 112(3):536-40. PubMed ID: 15382083
[TBL] [Abstract][Full Text] [Related]
19. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
20. Macrophages and abnormal BCL-6 or c-MYC gene expression affect the resistance of peritoneal B cells to induction of hyporesponsiveness.
Liou LB; Wu MW; Chao WJ
Scand J Immunol; 2009 May; 69(5):447-56. PubMed ID: 19508376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
